Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvakitug maintenance study in moderately to severely active ulcerative colitis
NL-OMON61051Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of duvakitug in autoimmune colitis (3 arms), sponsored by Sanofi. Primary endpoint: Clinical remission by modified Mayo Score. Started Oct 2026; status: recruiting.
02
Drugs
duvakitug
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON61051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61051.